Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE0005227235
Tue, 14.03.2023
Biotest AG
PRESS RELEASE
Biotest donates human albumin for earthquake victims in Turkey
Almost 2,000 severely affected victims can be supplied with human albumin
Close interaction with Turkish Red Crescent (Kizilay) and the Turkish-German Health Foundation e.V. (Türk Alman Saglik Vakfi)
Dreieich, 14 March 2023. As a manufacturer of life-saving [ … ]
Fri, 10.02.2023
Biotest AG
PRESS RELEASE
Biotest Supervisory Board appoints new Management Board member
Ainhoa Mendizabal will assume the position of Chief Financial Officer (CFO) on the Management Board on 15 February
Dreieich, 10 February 2023. The Supervisory Board of Biotest AG has appointed Ms Ainhoa Mendizabal (50) to the company's Management Board as Chief Financia [ … ]
Fri, 10.02.2023
Biotest AG
PRESS RELEASE
Biotest Supervisory Board appoints new Management Board member
Ainhoa Mendizabal will assume the position of Chief Financial Officer (CFO) on the Management Board on 15 February
Dreieich, 10 February 2023. The Supervisory Board of Biotest AG has appointed Ms Ainhoa Mendizabal (50) to the company's Management Board as Chief Financia [ … ]
Tue, 24.01.2023
Biotest AG
PRESS RELEASE
First patient treated with Cytotect® CP Biotest in study after heart and lung transplantation
High medical need due to severe cytomegalovirus (CMV) infections and resulting mortality after organ transplantation
Study will provide data to optimise treatment strategies with CMV hyperimmunoglobulins after heart and lung tr [ … ]
Thu, 19.01.2023
Biotest AG
PRESS RELEASE
Biotest receives "Innovation Champion of Sustainability" award
Biotest achieves very good 5th place in sustainability analysis by F.A.Z.-Institute
With its GoFuture sustainability initiative, Biotest aims to grow in line with social and ecological requirements.
Dreieich, 19 January 2023. The renowned F.A.Z. Institute [ … ]
Tue, 10.01.2023
Biotest AG
PRESS RELEASE
Biotest treats first COVID-19 patients with trimodulin in TRICOVID phase III trial
Trimodulin is a worldwide unique, innovative human plasma protein preparation in advanced development
Significant reduction in clinical deterioration and mortality expected in hospitalised patients with early systemic inflammation
German [ … ]
Thu, 08.12.2022
Biotest AG
PRESS RELEASE
First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins
High medical need for 300 million patients with chronic hepatitis B worldwide
Further development of hepatitis B immunoglobulins (HBIG) could offer patients new and much-needed treatment options
Biotest supports [ … ]
Thu, 08.12.2022
Biotest AG
PRESS RELEASE
First patient enrolled in phase II clinical trial for treatment of chronic hepatitis B with hyperimmunoglobulins
High medical need for 300 million patients with chronic hepatitis B worldwide
Further development of hepatitis B immunoglobulins (HBIG) could offer patients new and much-needed treatment options
Biotest supports [ … ]
Mon, 14.11.2022
Biotest AG
PRESS RELEASE
Biotest reports sales of € 361 million in the first nine months of 2022
Robust Q1-Q3 2022 sales in a challenging macroeconomic context
Biotest receives marketing authorization for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
Opening of seven new plasma centres in 2022, adding up to a plasma-center network [ … ]
Mon, 14.11.2022
Biotest AG
PRESS RELEASE
Biotest reports sales of € 361 million in the first nine months of 2022
Robust Q1-Q3 2022 sales in a challenging macroeconomic context
Biotest receives marketing authorization for new intravenous immunoglobulin Yimmugo® (IgG Next Generation)
Opening of seven new plasma centres in 2022, adding up to a plasma-center network [ … ]